利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.044 秒)

    Remedies with the use of hollow protein nanoparticles presenting growth factor or the like
    5.
    发明申请
    Remedies with the use of hollow protein nanoparticles presenting growth factor or the like 审中-公开
    使用具有生长因子等的中空蛋白质纳米粒子的补救措施

    公开(公告)号：US20060165726A1

    公开(公告)日：2006-07-27

    申请号：US10509248

    申请日：2003-03-05

    申请人： Shunichi Kuroda ,  Katsuyuki Tanizawa ,  Akihiko Kondo ,  Masakazu Ueda ,  Masaharu Seno ,  Hidehiko Iwabuki

    发明人： Shunichi Kuroda ,  Katsuyuki Tanizawa ,  Akihiko Kondo ,  Masakazu Ueda ,  Masaharu Seno ,  Hidehiko Iwabuki

    IPC分类号： A61K39/29 ,  A61K39/245 ,  A61K9/14

    CPC分类号： B82Y5/00 ,  A61K9/5068 ,  A61K48/00

    摘要： The invention provides a disease-treating drug, specifically acting particular cells or tissues, which is based on protein hollow nanoparticles. The drug's therapeutic effects are confirmed through animal experiments. The invention also provides a treatment method using the drug. The disease-treating drug comprises a substance to be transferred into a cell for treatment of a disease (for example, cancer-treating, thymidine kinase gene of herpes simplex virus type 1) encapsulated in hollow nanoparticles containing particle-forming protein (for example, hepatitis B virus surface antigen protein modified to lose infectivity to inherent hepatocyte and also display a growth factor) displaying, for example, a growth factor.

    摘要翻译： 本发明提供一种疾病治疗药物，特别是作用于基于蛋白质中空纳米颗粒的特定细胞或组织。 药物的治疗效果通过动物实验证实。 本发明还提供了使用该药物的治疗方法。 疾病治疗药物包含被包含在含有颗粒形成蛋白质的中空纳米颗粒中的用于治疗疾病（例如，1型单纯疱疹病毒的胸腺嘧啶激酶基因的癌症治疗，胸苷激酶基因）的细胞中的物质（例如， 乙型肝炎病毒表面抗原蛋白被修饰以丧失对固有肝细胞的感染性并且还显示生长因子），显示例如生长因子。

    Drug for treating liver diseases with the use of hollow protein nanoparticles
    6.
    发明申请
    Drug for treating liver diseases with the use of hollow protein nanoparticles 审中-公开
    使用中空蛋白纳米颗粒治疗肝脏疾病的药物

    公开(公告)号：US20060034869A1

    公开(公告)日：2006-02-16

    申请号：US10509252

    申请日：2003-03-05

    申请人： Shunichi Kuroda ,  Katsuyuki Tanizawa ,  Akihiko Kondo ,  Masakazu Ueda ,  Masaharu Seno ,  Hidehiko Iwabuki

    发明人： Shunichi Kuroda ,  Katsuyuki Tanizawa ,  Akihiko Kondo ,  Masakazu Ueda ,  Masaharu Seno ,  Hidehiko Iwabuki

    IPC分类号： A61K39/29 ,  A61K9/14 ,  C12Q1/68

    CPC分类号： B82Y5/00 ,  A61K9/5068 ,  A61K48/00

    摘要： The invention provides a drug for treating hepatic diseases with the use of hollow protein nanoparticles. The effectiveness of the drug has been proved by animal testing. The invention also provides a therapeutic method using such a drug. In a drug according to the present invention, a substance to be transferred into a cell for treating a hepatic disease (for example, a cancer treating gene such as a thymidine kinase gene derived from simple herpes virus) is encapsulated in hollow nanoparticles that have an ability to recognize a hepatocyte and are composed of a particle-forming protein (for example, hepatitis B virus surface-antigen protein).

    摘要翻译： 本发明提供了一种使用中空蛋白纳米颗粒治疗肝病的药物。 药物的有效性已经通过动物实验证明。 本发明还提供了使用这种药物的治疗方法。 在根据本发明的药物中，将被转移到用于治疗肝脏疾病的细胞中的物质（例如，衍生自简单疱疹病毒的胸腺嘧啶激酶基因等癌症治疗基因）被包封在具有 能够识别肝细胞并由形成颗粒的蛋白质（例如乙型肝炎病毒表面抗原蛋白质）组成。

    Hepatic cirrhosis model animal and method of constructing the same
    8.
    发明申请
    Hepatic cirrhosis model animal and method of constructing the same 审中-公开
    肝硬化模型动物及其构建方法

    公开(公告)号：US20060107338A1

    公开(公告)日：2006-05-18

    申请号：US10521411

    申请日：2003-07-14

    申请人： Shunichi Kuroda ,  Katsuyuki Tanizawa ,  Akihiko Kondo ,  Masakazu Ueda ,  Masaharu Seno

    发明人： Shunichi Kuroda ,  Katsuyuki Tanizawa ,  Akihiko Kondo ,  Masakazu Ueda ,  Masaharu Seno

    IPC分类号： A01K67/027

    CPC分类号： A01K67/0271 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2227/105 ,  A01K2267/035 ,  A61K49/0008

    摘要： The present invention provides a cirrhosis model animal having human hepatic tissues affected with cirrhosis. Anti-asialo GM1 antibodies are administered to a scid mouse which is an immune-deficiency animal, and its natural-killer-cell-dependent immune response capability is made defective, and then cirrhosis-patient-derived hepatic tissues are transplanted beneath a kidney membrane of the scid mouse, thereby producing the cirrhosis model animal. The cirrhosis model animal has the human hepatic tissues affected with cirrhosis, so that it is possible to use the cirrhosis model animal in development of a therapy and a therapeutic drug for cirrhosis.

    摘要翻译： 本发明提供了肝硬化患者肝硬化的肝硬化模型动物。 抗唾液酸GM1抗体被施用于作为免疫缺陷动物的scid小鼠，并且其天然杀伤细胞依赖性免疫应答能力被制成缺陷，然后将肝硬化患者来源的肝组织移植到肾膜下 的scid小鼠，从而产生肝硬化模型动物。 肝硬化模型动物患有肝硬化的人肝组织，因此可以使用肝硬化模型动物开发治疗和治疗药物用于肝硬化。